Germany takes 300 million euro stake in vaccine developer CureVac

FRANKFURT (Reuters) – Germany will take a stake of about 23% in unlisted biotech firm CureVac by backing a 300 million euro ($337 million) capital increase to fund the company’s further development of a COVID-19 vaccine.

The move was agreed with SAP co-founder Dietmar Hopp – who is an early backer and owner of a stake of more than 80% in CureVac – German Economy Minister Peter Altmaier and Hopp said in an online media briefing.

Reuters earlier reported that a state investment had been agreed.

Reporting by Ludwig Burger; Editing by Michelle Martin

View original article here Source

Related Posts